PLUS1
Best deals to access real time data! |
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
CHART Trader
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Immuron Ltd | IMRN | NASDAQ | Depository Receipt |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 3.8682 | 0.00 | 0.00 | 0.00 | 3.8682 | 09:29:40 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 3.75 | 4.14 | 0.39 | 9.42% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | 0.00 | USD |
Immuron Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | |
|---|---|---|---|---|---|
| 17.10M | 4.42M | -3.01M | -0.90 | - | 4.42M |
| Dividends Per Share | Dividend Yield | ||||
|---|---|---|---|---|---|
| - | - | 0.00% | - | - |
News Immuron
| Date | Time | Source | Heading |
|---|---|---|---|
| 11/21/2019 | 07:00 | GlobeNewswire Inc. | Immuron Plans Phase 3 trial for IMM-124E to Prevent.. |
| 11/21/2019 | 06:05 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 11/06/2019 | 06:12 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 11/06/2019 | 06:09 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 11/04/2019 | 11:30 | GlobeNewswire Inc. | Immuron Receives AUD $0.53M R&D Tax Concession Refund |
| 11/04/2019 | 06:16 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
| 10/29/2019 | 06:05 | Edgar (US Regulatory) | Report of Foreign Issuer (6-k) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
IMRN Historical
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| 5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.0% |
| Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's lead product candidate, IMM-124E, is a proprietary immunomodulator agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products. |
